The GCC's reputation as a brand drug stronghold is coming to an end. MT explores how the rise of generics is proving a success story for the subcontinent.
Start with a pharmaceutical market built almost entirely on imports. Add in a society weighted by chronic diseases, seeking every way to clamp down on healthcare costs.
Factor in the number of brand name drugs set to lose patent protection over the next few years. What you end up with is a prediction that over the next five years, generic drug manufacturers will dominate the GCC's pharmaceutical industry. And the biggest players, say experts, are likely to be Indian
No comments:
Post a Comment